| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8212971 | International Journal of Radiation Oncology*Biology*Physics | 2017 | 27 Pages |
Abstract
In patients with muscle-invasive UC who are not candidates for cystectomy, daily radiation combined with paclitaxel is an effective treatment strategy with a high completion rate and moderate toxicity. In patients with her2/neu-positive tumors, a group generally considered to have worse outcomes, the addition of trastuzumab appears to result in comparable efficacy and toxicity. Further biomarker-driven trials should be undertaken in advancing treatment of this challenging disease.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
M. Dror MD, PhD, Chen PhD, Huong T. MD, Douglas M. MD, Chin MD, Gregory P. MD, Jacqueline MD, R. Jeffrey MD, Luis MD, Brian MD, Asha MS, Howard MD, William MD,